Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Alentis Therapeutics AG
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07169734CT.gov A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intrahepatic Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ale.P03 (this asset) | Alentis Therapeutics AG | P1/2 | CC · 47 |
| Nivolumab | Virogin Biotech Canada Ltd | P2 | BB |
| Durvalumab | West China Hospital | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Shanghai 6th People's Hospital | P2 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | TriSalus Life Sciences, Inc. | P2 | B |
| Pembrolizumab | Shanghai 6th People's Hospital | P1/2 | B |
| Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | P2 | B |
+42 more in the Intrahepatic Cholangiocarcinoma cohort
Other indications for Ale.P03
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P1/2 | CCC · 48 |
| Cervical Squamous Cell Carcinoma | — | P1/2 | CC · 47 |
| Urothelial Carcinoma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ale.P03 in Intrahepatic Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/alep03-intrahepatic-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →